Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs Ketorolac for Postoperative Pain and Cognitive Dysfunction
NCT05132595Unknown
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in postoperative pain and Post-operative cognitive dysfunction (POCD) (4 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Cumulative Opioid Consumption at 72 hours. Status: unknown.
02
Drugs
esketamine
03
Conditions
postoperative painPost-operative cognitive dysfunction (POCD)
Beyond the preview
Go deeper on NCT05132595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132595.